info@mail.ucallm.com
From Immune Activation to Disease Pathogenesis — Empowering Comprehensive Autoimmune Research with Validated Antibody Solutions
Autoimmune diseases encompass a broad spectrum of chronic immune-mediated disorders in which breakdown of self-tolerance leads to inappropriate recognition of self-antigens and persistent immune activation. Disease progression is driven by complex interactions among autoreactive T cells, B cells, antigen-presenting cells, innate immune populations, cytokine networks, complement, and inflammatory signaling pathways, ultimately resulting in tissue-specific inflammation and organ dysfunction.
The molecular landscape of autoimmune disease extends beyond immune-cell activation alone. Dysregulated antigen presentation, co-stimulatory signaling, T-cell differentiation, B-cell maturation, autoantibody production, cytokine signaling, inflammasome activation, complement activity, and tissue–immune interactions can collectively establish a self-amplifying inflammatory environment.
Our validated antibody solutions support comprehensive investigation of autoimmune mechanisms—from immune-cell identity and activation to molecular signaling, inflammatory responses, tissue pathology, and therapeutic target validation.
Validated antibodies enable researchers to characterize:
Immune cell activation and differentiation
Cytokine and receptor signaling pathways
B-cell and T-cell mediated immune responses
Autoimmune inflammation-associated biomarkers
Disease-associated therapeutic targets
researchers can decode autoimmune mechanisms, identify disease biomarkers, and accelerate discoveries in immunology, inflammation research, precision medicine, and therapeutic development.
Autoimmune Disease Biomarker Antibody Portfolio
——Comprehensive Solutions for Immune Pathway Profiling, Disease Mechanism Discovery, and Therapeutic Target Validation
Autoimmune disease research requires integrated analysis of immune receptors, cytokine networks, inflammatory pathways, and immune regulatory mechanisms.
Our antibody portfolio provides validated research tools targeting key autoimmune pathways involved in:
Research Focus | Representative Biomarkers | Research Applications |
Pro-inflammatory Cytokine Signaling | TNF, IL6R, IL17A, IL17RA, IL23A (p19), IL12B (p40) | Characterization of inflammatory cytokine networks and immune activation |
B-cell Activation & Autoantibody Production | CD19, \ (CD20), BAFF, TNFSF13 , TNFRSF13B , TNFRSF13C, BTK | Analysis of B-cell maturation, survival, and autoantibody-mediated responses |
T-cell Activation & Immune Regulation | CD3, CTLA-4, PD-1, LAG-3, BTLA | Investigation of T-cell activation, exhaustion, and immune tolerance |
JAK-STAT Immune Signaling | JAK1, JAK2, JAK3, TYK2 | Evaluation of cytokine receptor signaling and therapeutic inhibition pathways |
Complement & Innate Immune Activation | C5AR1, FCGRT, TLR7, TLR8 | Study of innate immune activation and inflammatory amplification |
Integrin-Mediated Immune Trafficking | α4β7 integrin, S1PR1, PTK2/FAK, p-FAK Tyr397, TLN1 | Investigation of immune cell migration and tissue infiltration |
Inflammasome & Inflammatory Sensors | NLRP3, PADI4, CASP1, Cleaved Caspase-1 (Asp296), GSDMD, Cleaved GSDMD, Histone H3 citrullinated (R2/R8/R17) | Analysis of innate immune activation and NETosis-associated autoimmunity |
Core Autoimmune Disease Targets
——Molecular Drivers of Immune Dysregulation, Inflammation, and Therapeutic Intervention
Autoimmune diseases are driven by complex interactions between immune-cell activation, inflammatory cytokine networks, autoantibody production, antigen presentation, and tissue-specific immune injury. Comprehensive analysis of key immune targets enables researchers to investigate disease mechanisms, identify therapeutic opportunities, and develop precision immunomodulatory strategies.
Our antibody portfolio provides validated tools targeting major autoimmune pathways, including cytokine signaling, immune-cell activation, B-cell regulation, T-cell checkpoints, innate immune sensing, and tissue-specific autoimmune responses.
Disease Area | Key Pathogenic Pathways | Representative Targets |
Rheumatoid Arthritis (RA) | Cytokine-driven inflammation, synovial immune activation, fibroblast-like synoviocyte remodeling | TNF, IL6R, IL17A, IL23A, MS4A1, JAK1/JAK2/JAK3, SYK, MMP3, TNFSF11 (RANKL) |
Systemic Lupus Erythematosus (SLE) | B-cell hyperactivation, interferon signaling, immune-complex deposition | TNFSF13B (BAFF), IFNAR1, CD19, MS4A1, FCGRT, TLR7, TLR8, BTK |
Spondyloarthritis (SpA) | IL-23/IL-17 axis activation, inflammatory tissue remodeling | TNF, IL17A, IL17F, IL23A, JAK1, TYK2 |
Inflammatory Bowel Disease (IBD) | Intestinal immune activation, leukocyte trafficking, epithelial inflammation | TNF, IL12B, IL23A, ITGA4 + ITGB7, JAK1, TNFSF15 |
Multiple Sclerosis (MS) | CNS immune infiltration, autoreactive lymphocytes, neuroinflammation | CD20, CD19, S1PR1, GFAP, Iba1, MBP |
Autoimmune Vasculitis | B-cell activation, complement-mediated inflammation | CD20, C5aR1 |
Myasthenia Gravis (MG) | Autoantibody-mediated neuromuscular dysfunction | AChR, MuSK, FcRn, CD19/CD20 |
Type 1 Diabetes (T1D) | T-cell-mediated β-cell destruction, autoantigen recognition | CD3, GAD65, IA-2, ZnT8, Insulin |
Autoimmune Thyroid Disease | Organ-specific autoantibody production | TPO, Thyroglobulin |
Featured Autoimmune Research Panels
——Comprehensive Antibody Panels for Immune Profiling, Disease Mechanism Analysis, and Therapeutic Target Discovery
Autoimmune diseases involve complex interactions between immune cells, inflammatory mediators, and tissue-specific responses. Our curated antibody panels enable systematic investigation of immune activation, inflammatory signaling, autoimmune cell populations, and disease-associated therapeutic targets.
n Rheumatoid Arthritis Inflammation Panel—Profiling Cytokine Networks and Immune Activation Pathways
Key Markers
TNF-α | IL-6R | IL-17A | IL-23 | JAK1/JAK3 | CD20 |
n Lupus Autoimmunity & B-cell Regulation Panel—Decoding Autoantibody Production and Immune Dysregulation
Key Markers
BAFF | IFNAR1 | CD19 | CD20 | TLR7/TLR8 | BTK |
n Autoimmune Neuroinflammation and Glial Activation Panel—Investigating Immune-Mediated CNS Damage and Repair Mechanisms
Key Markers
GFAP | CD20 | MBP | Iba1 | p-TBK1 |
n Intestinal Immune Remodeling Panel—Understanding Immune Cell Recruitment and Chronic Inflammation
Key Markers
TNF-α | IL-23 | α4β7 integrin | JAK1 | TNFSF15 |
Why Researchers Choose Our Autoimmune Disease Antibody Solutions
Validated Immune Targets. Comprehensive Disease Panels. Reliable Translational Insights.
Our antibody portfolio supports complete autoimmune research workflows:
Research Challenge | Our Solution |
How can I study inflammatory cytokine activation? | TNF-α, IL-6R, IL-17, IL-23 pathway antibodies |
How can I analyze autoimmune B-cell responses? | CD19, CD20, BAFF, BTK antibody solutions |
How can I investigate immune signaling pathways? | JAK/TYK2 pathway antibodies |
How can I characterize autoimmune tissue inflammation? | Multiplex IF/IHC immune marker panels |
How can I explore emerging therapeutic targets? | NLRP3, checkpoint, and immune regulatory antibodies |
How can I improve experimental reproducibility? | Validated antibodies optimized for WB, IF, IHC, flow cytometry, and multiplex applications |
Key reference
1. Xiaoshuang Song, Hantian Liang (2025). Autoimmune Diseases: Molecular Pathogenesis and Therapeutic Targets. MedComm, 2025; 6:e70262.
2. Lili Balogh, Katalin Oláh (2024). Novel and potential future therapeutic options in systemic autoimmune diseases.Front Immunol. 2024 Mar 15;15:1249500.
3. May A Alsayb (2025). Innovations in immunotherapy for autoimmune diseases: recent breakthroughs and future directions.Front Immunol. 2025 Sep 17;16:1647066.
4. Yi Song, Jian Li(2024). Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders. Signal Transduction and Targeted Therapy (2024) 9:263.
5. Tong Wang, Tong Fu (2025). Advances and prospects of CAR-T cell therapy in autoimmune disease treatment. Medicine (2025) 104:47.